# High-Density Lipoprotein (HDL) Modulation and Endothelial Function

> **NCT00150722** · PHASE3 · COMPLETED · sponsor: **University of Calgary** · enrollment: 75 (actual)

## Conditions studied

- Atherosclerosis

## Interventions

- **DRUG:** atorvastatin (or other tolerated statin + Niaspan/placebo)

## Key facts

- **NCT ID:** NCT00150722
- **Lead sponsor:** University of Calgary
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2008-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00150722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00150722, "High-Density Lipoprotein (HDL) Modulation and Endothelial Function". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00150722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*